01. June 2017
SynAbs is pleased to announce that almost two years after being found and thanks to excellent financial results, we have decided to move to the SynAbs S.A. facilities and head office from Brussels and Louvain la Neuve to the Gosselies Biopark, where we will be part of a biotech ecosystem focused on immunology. More specifically, we will be hosted by the i-Tech Incubator, renting 155 sqm euipped with brand new labs to enable us to better serve our custom antibody and immunoassay customers...
10. May 2017
Wallonia Biotech Coaching, the Walloon coach of innovation in the life sciences, has recently celebrated its 10th anniversary! Perfectly in tune with the crucial stakes in the development of life sciences, WBC has rapidly made a name for itself as the real springboard for many Walloon companies that are part of this sector. Its mission is to help the development of innovative and competitive companies progressing into Biotech sector, such as SynAbs.
05. May 2017
SynAbs is proud to announce strategic deal with successful company Sapphire. Sapphire already distributes major references in the field of monoclonal antibodies and will consequently extends its catalogue with unique mAbs references from SynAbs. Under the terms of the agreement, Sapphire will have access to unique portfolio of rats and guinea pigs mAbs to address USA & Canada territories needs in R&D and IVD fields. Brian Conkle - VP Sales & Marketing Sapphire 795 Highland Dr 48108...
13. January 2017
SynAbs is proud to announce strategic deal with successful company Dianova. Dianova has already demonstrated a huge knowledge and expertise in monoclonal antibodies and will consequently extend its catalogue with unique mAbs references from SynAbs. Under the terms of the agreement, Dianova will have access to unique portfolio of rats and guinea pigs mAbs to address German territory needs in R&D and IVD fields. Kristine Fischer - Director Business Development dianova GmbH Warburgstrasse 45...
19. September 2016
SynAbs is proud to appoint LuBioSience as its new distributor for Switzerland. LuBioScience has a seasoned team and expertise in selling biochemicals, including the specific monoclonal antibodies of SynAbs, in particular the anti-species which should be welcomed by the Swiss Biopharma R&D and IVD sector. Roland Schärli - CEO LuBioScience GmbH Töpferstrasse 5 PO Box 6004 Lucerne Switzerland Phone: +41 41 417 02 80 - Fax: +41 41 417 02 89 info@lubio.ch www.lubio.ch
03. August 2016
Monoclonal antibodies development has been limited for a long time to only two species : mice and rats. However, the immune systems of mice and rats are not the most suitable in terms of humoral response to certain antigens, such as human antigens like glucagon. Indeed, the protein sequence of glucagon is the same in mice, rats and human (fig. 1). Small not immunogenic antigens, such as antibiotics or toxins, generally failed to trigger an immune response in such species. This is why some...
03. August 2016
Aflatoxins are a worldwide health problem as many as 5 billion persons may be exposed. Children are particularly affected by aflatoxin exposure, which leads to stunted growth, delayed development, liver damage and liver cancer. Adults have a higher tolerance but are also at risk. Aflatoxins have a negative economic impact on agriculture through reduced marketing options for crops and adverse health effects on livestock. Losses due to aflatoxins annually cost $ 900 million in Indonesia, the...